Browse by Medical Category
Accepting New Patients
Go To Programs
MassGeneral Hospital for Children
Go To Specialties
Alexa Boer Kimball, MD, MPH, is an experienced and accomplished academic investigator,leader and administrator. She is Senior Vice President of the Massachusetts General Physician Organization, which employs more than 2500 physicians, and previously served as Medical Director (chief medical officer) of this organization. A Professor of Dermatology at Harvard Medical School, she leads the Clinical Unit for Research Trials and Outcomes in Skin at Massachusetts General Hospital (MGH) with a focus on psoriasis and hidradenitis suppurativa. She has published over 250 papers, is the author of the book "100 Questions and Answers about Psoriasis," which has been translated into Spanish, Greek, and Korean, and editor of "Dermatologic Diseases and Cumulative Life Course Impairment."
Dr. Kimball is widely recognized for her research on physician workforce economics, quality of life, and outcomes, for which she was awarded the American Skin Association Research Award for Health Policy and Medical Education and the MGH Bowditch Prize for increasing quality of care while reducing costs.
Dr. Kimball received her MD from the Yale University School of Medicine and her MPH from the Johns Hopkins School of Public Health, with dual bachelor's degrees in molecular biology and public and international affairs from Princeton University. She completed her residency in dermatology at Stanford University Medical Center and a clinical research fellowship at the National Institutes of Health. Dr. Kimball has served on multiple non-profit Boards including: the Society for Investigative Dermatology, where she was elected Vice President, the Massachusetts Foundation for the Humanities and Public Policy, and the Hidradenitis Suppurativa Foundation. She is incoming President of the International Psoriasis Council.
View my most recent publications at PubMed
1: Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2015 Jul 22. [Epub ahead of print]2: Percac-Lima S, Cronin PR, Ryan DP, Chabner BA, Daly EA, Kimball AB. Patient navigation based on predictive modeling decreases no-show rates in cancer care. Cancer. 2015 May 15;121(10):1662-70.3: Kim GE, Seidler E, Kimball AB. Effect of Age at Diagnosis on Chronic Quality of Life and Long-Term Outcomes of Individuals with Psoriasis. Pediatr Dermatol. 2014 Dec 29. doi: 10.1111/pde.12416. [Epub ahead of print]4: Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, Donahue KR, Kimball AB. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015 Apr;151(4):375-81.
The results of two phase 3 clinical trials that led to FDA approval of adalimumab for treatment of the chronic inflammatory skin disease hidradenitis suppurativa are being published in the August 4 New England Journal of Medicine.
Browse the latest local and national news articles featuring stories from basic research to innovative breakthroughs in cosmetic dermatology.
In preparation for the final Partners eCare launch on April 2, Alexa B. Kimball, MD, senior vice president of the MGPO, provided some insight into the looming launch, answering questions to help all staff get ready.
Alexa Kimball, MD, MPH, medical director of the MGPO, received the 2014 Nathaniel Bowditch Prize on April 29.
You may be eligible to participate in a research study of an investigational medication.
Back to Top